Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which has completed phase IIa clinical trials for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/21/2020 11:30 PST] PLX Expected to Trade Up After Bullish Patterns Develop
• [02/20/2020 10:10 PST] Protalix BioTherapeutics, Inc. (NYSE:PLX), Up By 100.00% ($3.29) From $3.290 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/18/2020 07:17 PST] PLX Expected to Trade Up After Bullish Patterns Develop
• [01/17/2020 10:10 PST] Protalix BioTherapeutics, Inc. (NYSE:PLX), Down By 100.00% ($4.11) From $4.110 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [01/13/2020 07:53 PST] PLX Expected to Trade Down After Bearish Patterns Develop
• [01/02/2020 09:51 PST] Protalix BioTherapeutics, Inc. (NYSE:PLX), Up By 100.00% ($3.28) From $3.280 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/02/2020 07:39 PST] PLX Expected to Trade Up After Bullish Patterns Develop
• [12/31/2019 10:29 PST] Protalix BioTherapeutics, Inc. (NYSE:PLX), Up By 100.00% ($2.63) After BUYINS.NET SqueezeTrigger Report Released on Friday, December 20th 2019 at a Price of $2.626.
• [12/27/2019 10:10 PST] Protalix BioTherapeutics, Inc. (NYSE:PLX), Up By 100.00% ($2.57) From $2.570 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/27/2019 07:50 PST] PLX Expected to Trade Up After Bullish Patterns Develop